Construction of gene subgroups of Crohn disease based on transcriptome data

Background: The global prevalence of Crohn disease (CD), a chronic inflammatory disease of the intestine, has been increasing; however, the etiology and pathogenesis of this disease have not been fully elucidated. Therefore, in the present study, we aimed to better understand the molecular mechanisms underlying CD to aid the development of novel therapeutic strategies for this condition. Methods: Based on the transcriptome data from patients with CD, this study used an unsupervised learning method to construct gene co-expression molecular subgroups and the R and SPSS software to identify the biological, clinical, and genetic characteristics and signatures of each subgroup. Results: Two subgroups were analyzed. Compared to subgroup II, subgroup I consisted of older patients with a more limited range of disease presentation and had a higher number of smokers. The specific genes associated with this subgroup, including CDKN2B, solute carrier family 22 member 5, and phytanoyl-CoA 2-hydroxylase, can be targeted for managing intestinal dysbacteriosis. The number of patients showing infiltrating lesions was higher, the number of smokers was lower, and CD severity was worse in patients in subgroup II than those in subgroup I. The specific genes relevant to subgroup II included cluster of differentiation 44, tryptophanyl-tRNA synthetase, and interleukin 10 receptor, alpha subunit, which may be related to viral infection. Conclusion: The present study segregated patients with CD into 2 subgroups; the findings reported herein provide a new theoretical basis for the diagnosis and treatment of CD and could aid a thorough identification of potential therapeutic targets for this disease.

[1]  Yifan Yuan,et al.  Identification of immune infiltration and cuproptosis-related subgroups in Crohn’s disease , 2022, Frontiers in Immunology.

[2]  Jie Pan,et al.  CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual specificity phosphatase 1. , 2021, Carcinogenesis.

[3]  Bing Yu,et al.  Diagnostic and Predictive Value of Immune-Related Genes in Crohn’s Disease , 2021, Frontiers in Immunology.

[4]  Ziqing Ye,et al.  Intestinal dysbiosis in pediatric Crohn's disease patients with IL10RA mutations , 2020, World journal of gastroenterology.

[5]  Xin Hu,et al.  Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma. , 2019, Annals of translational medicine.

[6]  G. Kaplan,et al.  Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study , 2019, Gut.

[7]  M. Mínguez Pérez,et al.  Crohn's disease. , 2018, Medicina clinica.

[8]  B. Han,et al.  Association of CDKN2A/CDKN2B with inflammatory bowel disease in Koreans , 2018, Journal of gastroenterology and hepatology.

[9]  B. Dogan,et al.  Rifaximin decreases virulence of Crohn’s disease-associated Escherichia coli and epithelial inflammatory responses , 2018, The Journal of Antibiotics.

[10]  Daniel E. Miller,et al.  Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity , 2018, Nature Genetics.

[11]  J. Kisiel,et al.  Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's Disease. , 2017, Gastroenterology clinics of North America.

[12]  Rongling Wu,et al.  Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease , 2017, World journal of gastroenterology.

[13]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[14]  S. Ng,et al.  Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. , 2016, The lancet. Gastroenterology & hepatology.

[15]  B. Staels,et al.  Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs? , 2015, Trends in Endocrinology & Metabolism.

[16]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[17]  Kang-Moon Lee,et al.  Crohn's disease in Korea: past, present, and future , 2014, The Korean journal of internal medicine.

[18]  M. Barbanti,et al.  Rifaximin: beyond the traditional antibiotic activity , 2014, The Journal of Antibiotics.

[19]  F. He,et al.  The GTPase-activating protein GIT2 protects against colitis by negatively regulating Toll-like receptor signaling , 2014, Proceedings of the National Academy of Sciences.

[20]  C. Klein,et al.  Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. , 2014, Immunity.

[21]  S. Schreiber,et al.  Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process , 2012, The American Journal of Gastroenterology.

[22]  Brian J. Bennett,et al.  Unraveling Inflammatory Responses using Systems Genetics and Gene-Environment Interactions in Macrophages , 2012, Cell.

[23]  S. Travis,et al.  IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease , 2011, The Journal of experimental medicine.

[24]  R. Xavier,et al.  Virus-Plus-Susceptibility Gene Interaction Determines Crohn's Disease Gene Atg16L1 Phenotypes in Intestine , 2010, Cell.

[25]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[26]  P. Deloukas,et al.  Signatures of mutation and selection in the cancer genome , 2010, Nature.

[27]  M. Reed,et al.  Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide , 2009, The Journal of experimental medicine.

[28]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[29]  H. Inoue,et al.  Arf GAPs and Their Interacting Proteins , 2007, Traffic.

[30]  P. Murray Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. , 2006, Current opinion in pharmacology.

[31]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[32]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[33]  Laurent Beaugerie,et al.  High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. , 2004, Gastroenterology.

[34]  L. Greco,et al.  Effects of Disease Activity on Anti–Saccharomyces cerevisiae Antibodies: Implications for Diagnosis and Follow-up of Children with Crohn's Disease , 2004, Inflammatory bowel diseases.

[35]  Jérôme Boudeau,et al.  Regulatory and functional co‐operation of flagella and type 1 pili in adhesive and invasive abilities of AIEC strain LF82 isolated from a patient with Crohn's disease , 2003, Molecular microbiology.

[36]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[37]  R. Modigliani,et al.  Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. , 1992, Gastroenterology.

[38]  A. Saftoiu,et al.  An unusual onset of Crohn's disease with oral aphthosis, giant esophageal ulcers and serological markers of cytomegalovirus and herpes virus infection: a case report and review of the literature. , 2019, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[39]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[40]  I. Leodolter [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.

[41]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .